Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 12/20 | 0.53 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4530116 | 0.85 | TLR7 (0.65) | TLR7TLR8 | |
| SCHEMBL4531387 | 0.83 | TLR7 (0.50) | TLR7FKBP1ANPSR1ALDH1A1TLR8 | |
| SCHEMBL4535266 | 0.83 | TLR7 (0.58) | TLR7TLR8 | |
| SCHEMBL4520809 | 0.82 | TLR7 (0.59) | TLR7TLR8 | |
| SCHEMBL4523971 | 0.81 | TLR7 (0.52) | TLR7FKBP1ATLR8 | |
| SCHEMBL4529799 | 0.80 | TLR7 (0.61) | TLR7TLR8 | |
| SCHEMBL4532165 | 0.79 | TLR7 (0.62) | TLR7TLR8 | |
| SCHEMBL1774529 | 0.74 | FKBP1A (0.40) | TLR7FKBP1ANPSR1ALDH1A1TLR8 | |
| SCHEMBL4531190 | 0.73 | TLR7 (0.71) | TLR7TLR8 | |
| SCHEMBL4533711 | 0.73 | TLR7 (0.51) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658666-B2 | Substituted imidazoquinolines and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658666-B2 | Substituted imidazoquinolines and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658666-B2 | Substituted imidazoquinolines and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-02-25 | — | — | US | disclosed |
| US-20090099161-A1 | Substituted Imidazoquinolines and Imidazonaphthyridines | COLEY PHARMACEUTIAL GROUP, INC. (NY) | 2009-04-16 | — | — | US | disclosed |
| US-20090099161-A1 | Substituted Imidazoquinolines and Imidazonaphthyridines | COLEY PHARMACEUTIAL GROUP, INC. (NY) | 2009-04-16 | — | — | US | disclosed |
| US-20090099161-A1 | Substituted Imidazoquinolines and Imidazonaphthyridines | COLEY PHARMACEUTIAL GROUP, INC. (NY) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099161-A1 | Substituted Imidazoquinolines and Imidazonaphthyridines | IL2, EIF2AK2, IFNG | TLR7 35/4885FKBP1A 1116/4885NPSR1 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.